Niagen Bioscience (NAGE) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 net sales came in at $27.2 million, down 20% year over year and below the consensus estimate of roughly $31.9 million.
• Niagen Bioscience posted a net loss of $1.2 million, or $0.01 per diluted share, versus net income of $4.6 million, or $0.06 per diluted share, in the year-ago quarter.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) stayed positive at about $0.5 million, and the company generated roughly $2.6 million in operating cash flow.
• Tru Niagen revenue declined 10% year over year to $23.3 million, while the Niagen Ingredients business contributed $3.8 million.
• The company ended the quarter with $69.5 million in cash, a debt-free balance sheet, and $83.3 million in working capital.
• For full-year 2026, management reiterated expectations for direct website revenue growth of 15% to 20% and overall e-commerce growth of approximately 5%.
• For additional context on Niagen Bioscience, explore its Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Readers looking for data-driven trading ideas can also explore Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

Niagen Bioscience is a healthy-aging company built around NAD+ (nicotinamide adenine dinucleotide), a coenzyme that declines with age, and its flagship ingredient Niagen, a patented form of nicotinamide riboside. The third quarter of 2026 tested whether the company can sustain its growth narrative while navigating near-term commercial headwinds. After a strong fiscal 2025 and double-digit revenue expansion in recent years, investors were watching closely to see whether softer consumer demand and spending on new initiatives would pressure the top line. Because Niagen operates across consumer products, ingredients, and pharmaceutical channels, this report also offers a read on the broader healthy-aging and supplement market, making it a meaningful checkpoint for both growth-focused and value-oriented investors.

Reported Results

For the third quarter ended September 30, 2026, Niagen Bioscience reported net sales of $27.2 million, a 20% decline from $34.0 million in the same period last year and below the consensus estimate of about $31.9 million. The company recorded a net loss of $1.2 million, or $0.01 per diluted share, compared with net income of $4.6 million, or $0.06 per diluted share, a year earlier, missing the consensus estimate of breakeven results.

Within revenue, Tru Niagen contributed $23.3 million, down 10% year over year, while the Niagen Ingredients segment generated $3.8 million, including $3.4 million of food-grade Niagen and $425,000 of pharmaceutical-grade Niagen. Despite the top-line decline, the company maintained positive adjusted EBITDA of approximately $0.5 million and generated about $2.6 million in operating cash flow during the quarter. Niagen Bioscience ended the period with $69.5 million in cash, no debt, and $83.3 million in working capital.

Management also reiterated full-year 2026 expectations for direct website revenues to grow 15% to 20% and for overall e-commerce to grow approximately 5% year over year.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Niagen Bioscience, the AI Screener can serve as a practical starting point for refining watchlists and spotting emerging opportunities.

Market Reaction and Investor Sentiment

Niagen Bioscience shares fell in after-hours trading on November 4, 2026, after the results were released, reflecting investor disappointment over the revenue miss and the swing to a net loss. The roughly 9% after-hours decline suggested that the market had anticipated a steadier performance, particularly given the company's history of top-line growth. Sentiment around the stock has been under pressure for much of 2026, with the share price trading well below its 52-week high and a substantial portion of the float held short. Against that backdrop, the softer Tru Niagen results and elevated spending on brand, retail, and research initiatives weighed on confidence, even as the company's cash position and debt-free balance sheet offered a measure of stability.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Niagen Bioscience can convert its reiterated full-year guidance into actual revenue improvement. The company expects direct website revenue to grow 15% to 20% in 2026, which makes the fourth quarter a critical test of demand recovery in its core e-commerce channel.

Several initiatives could shape the trajectory from here. The company is expanding pharmaceutical-grade Niagen through Niagen Plus and advancing its skincare portfolio, including the early launch of Niagen NanoCloud, which management described as generating strong early sales. A recently launched brand campaign and broader retail distribution may also support the consumer business, though increased selling and marketing expenses are expected to continue.

Cost trends will remain in focus, as the company anticipates higher research and development and general and administrative spending to support its pipeline, including the preclinical and IND-enabling (Investigational New Drug) development of NB4168. Management also noted that litigation-related expenses were elevated during the quarter and could ease once those matters are resolved.

Finally, the strength of the balance sheet, with $69.5 million in cash and no debt, provides flexibility as the company funds these growth initiatives. Investors will likely monitor whether operating cash flow remains positive, whether ingredient and pharmaceutical revenue accelerate, and whether the consumer segment stabilizes heading into the holiday quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations